Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4394 Combination Therapy in Prostate Cancer
CTR20260457Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-4394 in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Primary endpoints: Recommended phase 2 dose (RP2D), Incidence and severity of adverse events and 1 more. Started Apr 2026; status: active.
02
Drugs
SHR-4394
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20260457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260457.